Syncom Formulations (India) Limited (SYNCOMF.NS)
INR 21.04
(-0.14%)
INR 21.04
(-0.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 46.21 Million INR | -94.39% |
| 2022 | 823.01 Million INR | 42.95% |
| 2021 | 575.74 Million INR | -3.15% |
| 2020 | 594.46 Million INR | 1100.26% |
| 2019 | -59.43 Million INR | -513.88% |
| 2018 | 14.35 Million INR | -87.84% |
| 2017 | 118.05 Million INR | 99.01% |
| 2016 | 59.31 Million INR | 8323.78% |
| 2015 | -721.31 Thousand INR | 89.64% |
| 2014 | -6.96 Million INR | 64.69% |
| 2013 | -19.72 Million INR | -15.8% |
| 2012 | -17.03 Million INR | 47.34% |
| 2011 | -32.34 Million INR | -207.05% |
| 2010 | 30.21 Million INR | 841.54% |
| 2009 | 3.2 Million INR | -96.06% |
| 2008 | 81.55 Million INR | 71.75% |
| 2007 | 47.48 Million INR | -1.27% |
| 2006 | 48.09 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 708.96 Million INR | -13.86% |
| 2023 Q4 | 46.21 Million INR | -92.47% |
| 2023 FY | 46.21 Million INR | -94.39% |
| 2023 Q2 | 799.18 Million INR | 12.73% |
| 2023 Q3 | 613.88 Million INR | -23.19% |
| 2022 Q4 | 823.01 Million INR | 20.68% |
| 2022 FY | 823.01 Million INR | 42.95% |
| 2022 Q1 | 417.83 Million INR | -27.43% |
| 2022 Q2 | 902.11 Million INR | 115.9% |
| 2022 Q3 | 681.97 Million INR | -24.4% |
| 2021 Q3 | 959.66 Million INR | 50.01% |
| 2021 Q2 | 639.73 Million INR | -13.66% |
| 2021 Q1 | 740.93 Million INR | 24.64% |
| 2021 FY | 575.74 Million INR | -3.15% |
| 2021 Q4 | 575.74 Million INR | -40.01% |
| 2020 Q1 | 92.26 Million INR | 255.25% |
| 2020 Q4 | 594.46 Million INR | 322.04% |
| 2020 Q3 | 140.85 Million INR | 764.86% |
| 2020 Q2 | -21.18 Million INR | -122.96% |
| 2020 FY | 594.46 Million INR | 1100.26% |
| 2019 Q1 | 78.73 Million INR | 448.32% |
| 2019 Q2 | 26.61 Million INR | -66.2% |
| 2019 Q3 | 65.2 Million INR | 145.02% |
| 2019 FY | -59.43 Million INR | -513.88% |
| 2019 Q4 | -59.43 Million INR | -191.15% |
| 2018 Q3 | 66.05 Million INR | -5.66% |
| 2018 Q2 | 70.01 Million INR | -31.62% |
| 2018 Q1 | 102.38 Million INR | -13.27% |
| 2018 FY | 14.35 Million INR | -87.84% |
| 2018 Q4 | 14.35 Million INR | -78.26% |
| 2017 FY | 118.05 Million INR | 99.01% |
| 2017 Q1 | 65.19 Million INR | 9.91% |
| 2017 Q4 | 118.05 Million INR | 0.0% |
| 2016 Q4 | 59.31 Million INR | 0.0% |
| 2016 FY | 59.31 Million INR | 8323.78% |
| 2015 FY | -721.31 Thousand INR | 89.64% |
| 2015 Q4 | -721.31 Thousand INR | 0.0% |
| 2015 Q2 | -35.45 Million INR | 0.0% |
| 2014 Q4 | -6.96 Million INR | 0.0% |
| 2014 Q2 | 32.77 Million INR | 0.0% |
| 2014 FY | -6.96 Million INR | 64.69% |
| 2013 Q4 | -19.72 Million INR | -151.93% |
| 2013 FY | -19.72 Million INR | -15.8% |
| 2013 Q3 | 37.98 Million INR | 210905.56% |
| 2013 Q2 | 18 Thousand INR | -99.95% |
| 2013 Q1 | 37.56 Million INR | 320.55% |
| 2012 FY | -17.03 Million INR | 47.34% |
| 2012 Q2 | -52.45 Million INR | 0.0% |
| 2012 Q3 | 40.42 Million INR | 177.07% |
| 2012 Q4 | -17.03 Million INR | -142.13% |
| 2011 FY | -32.34 Million INR | -207.05% |
| 2010 FY | 30.21 Million INR | 841.54% |
| 2009 FY | 3.2 Million INR | -96.06% |
| 2008 FY | 81.55 Million INR | 71.75% |
| 2007 FY | 47.48 Million INR | -1.27% |
| 2006 FY | 48.09 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 859.94 Million INR | 94.626% |
| Ind-Swift Limited | 9.5 Billion INR | 99.514% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 98.599% |
| Sakar Healthcare Limited | 790.93 Million INR | 94.157% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 98.749% |
| Innova Captab Limited | 2.33 Billion INR | 98.02% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.116% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 100.922% |
| Morepen Laboratories Limited | -231.17 Million INR | 119.99% |
| Mankind Pharma Limited | -1.74 Billion INR | 102.643% |
| Sequent Scientific Limited | 4.17 Billion INR | 98.894% |
| Wanbury Limited | 1.1 Billion INR | 95.821% |
| Laurus Labs Limited | 24.35 Billion INR | 99.81% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 99.249% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 101.626% |
| Alembic Limited | 66.9 Million INR | 30.925% |
| Hikal Limited | 7.96 Billion INR | 99.42% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 98.805% |
| Neuland Laboratories Limited | -214.05 Million INR | 121.588% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 98.362% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 101.078% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 104.196% |
| Themis Medicare Limited | 764.96 Million INR | 93.959% |
| RPG Life Sciences Limited | -364.7 Million INR | 112.671% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 98.819% |
| Lupin Limited | 19.38 Billion INR | 99.762% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 118.574% |
| Wockhardt Limited | 18.27 Billion INR | 99.747% |
| Vaishali Pharma Limited | 119.13 Million INR | 61.211% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 98.231% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 103.325% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 99.829% |
| FDC Limited | -57.75 Million INR | 180.016% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 99.642% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 61.503% |
| Eris Lifesciences Limited | 13.8 Billion INR | 99.665% |
| Venus Remedies Limited | -267.7 Million INR | 117.262% |
| ZIM Laboratories Limited | 983.6 Million INR | 95.302% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 103.991% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 112.607% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 100.839% |
| Shilpa Medicare Limited | 9.06 Billion INR | 99.49% |
| Albert David Limited | -278.36 Million INR | 116.601% |
| Ajanta Pharma Limited | -954.9 Million INR | 104.839% |
| Hester Biosciences Limited | 2.29 Billion INR | 97.983% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 68.125% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 99.539% |
| Gufic Biosciences Limited | 3.19 Billion INR | 98.553% |
| Windlas Biotech Limited | -273.04 Million INR | 116.925% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 101.968% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 84.471% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 95.264% |
| Granules India Limited | 9.28 Billion INR | 99.502% |
| Aarti Drugs Limited | 5.54 Billion INR | 99.167% |
| Bal Pharma Limited | 1.26 Billion INR | 96.343% |
| Alkem Laboratories Limited | -1.6 Billion INR | 102.871% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.064% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 136.205% |
| Medicamen Biotech Limited | 160.31 Million INR | 71.175% |
| Unichem Laboratories Limited | 931.91 Million INR | 95.041% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 79.902% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 350.52% |
| Valiant Laboratories Limited | 649.9 Million INR | 92.89% |
| Orchid Pharma Limited | -1.31 Billion INR | 103.517% |
| Medico Remedies Limited | 78.67 Million INR | 41.265% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 101.113% |
| Ipca Laboratories Limited | 11.41 Billion INR | 99.595% |
| Brooks Laboratories Limited | 49.48 Million INR | 6.616% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.991% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.855% |
| NATCO Pharma Limited | -5.81 Billion INR | 100.794% |
| Suven Life Sciences Limited | -1.63 Billion INR | 102.83% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 97.609% |
| Strides Pharma Science Limited | 23.25 Billion INR | 99.801% |
| Indoco Remedies Limited | 6.47 Billion INR | 99.286% |
| Alpa Laboratories Limited | 35.36 Million INR | -30.676% |
| Lasa Supergenerics Limited | 205.79 Million INR | 77.546% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 104.907% |